Last updated on August 2019

Real-life Effectiveness of Vortioxetine in Depression


Brief description of study

Worldwide Major Depressive Disorder (MDD) has significant negative personal, societal and economic consequences.

Vortioxetine (Brintellix) is a new antidepressant authorized since 2013. Despite evidence generated from clinical trials which demonstrate that vortioxetine is an efficacious, well-tolerated antidepressant, there is a need to determine the effectiveness of vortioxetine in real life routine practice.

The study aim is to examine the real-life effectiveness of vortioxetine on functioning, depressive symptom relief, cognition and quality of life.

This is an observational, multi-national, study in patients with MDD initiating treatment with vortioxetine. Information will be collected by the physician, from the patient and their medical record at three time points - baseline, week 12 and week 24 (end of follow-up). This study will be conducted in six countries. In total 2,100 patients are planned for enrolment.

Clinical Study Identifier: NCT03555136

Find a site near you

Start Over

Clinique Villa Bleue

Angouleme, France
2.44miles
  Connect »

Clinique Villa Bleue (FR0008)

Angouleme, France
2.44miles
  Connect »